R
Robert Michael Wallis
Researcher at Pfizer
Publications - 11
Citations - 1197
Robert Michael Wallis is an academic researcher from Pfizer. The author has contributed to research in topics: Darifenacin & PDE5 drug design. The author has an hindex of 8, co-authored 11 publications receiving 1121 citations.
Papers
More filters
Journal ArticleDOI
Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
TL;DR: Sildenafil alone had no direct effect on platelet function, but it potentiated the in vitro antiaggregatory activity of sodium nitroprusside on rabbit and human platelets, suggesting that sildenAFil may potentiate the hypotensive effects of nitric oxide donor agents on the vasculature.
Journal ArticleDOI
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines
H. G. Laverty,Charles Benson,Elizabeth J. Cartwright,Michael J. Cross,Christopher J. Garland,Timothy R. Hammond,Cameron J. Holloway,Nick McMahon,J. Milligan,B.K. Park,Munir Pirmohamed,Chris Pollard,John Radford,N. Roome,P. Sager,Sarabjeet Singh,Tobias Suter,Willi Suter,Andrew W. Trafford,Paul G.A. Volders,Robert Michael Wallis,Roslyn Weaver,M. York,J.-P. Valentin +23 more
TL;DR: In order to understand, address and ultimately reduce cardiovascular safety liabilities of new therapeutic agents there is an urgent need to address three major questions.
Journal ArticleDOI
Integrated risk assessment and predictive value to humans of non-clinical repolarization assays
TL;DR: It is concluded that non‐clinical assays predict the risk of compounds to prolong the QT interval and cause TdeP in humans if the mechanism is through inhibition of the hERG current.
Journal ArticleDOI
Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society.
Derek J. Leishman,T.W. Beck,Noel Dybdal,David J. Gallacher,Brian Guth,Mark Holbrook,Brian M. Roche,Robert Michael Wallis +7 more
TL;DR: The Safety Pharmacology Society brought together a group of over 50 experts to discuss best practices for dog and monkey cardiovascular assessments in safety pharmacology and toxicology studies in order to build overall confidence in the ability of a study to test a given hypothesis.
Journal ArticleDOI
Muscarinic antagonists in development for disorders of smooth muscle function.
TL;DR: The M3 over M1 and M2 selectivity of darifenacin was confirmed in a range of animal models and inhibited intestinal motility at doses lower than those which inhibit gastric acid secretion, increase heart rate or inhibit salivary secretion.